FICHIT

Je m'inscris

FOLLICUM

0/5 (0 note(s))
Note donnée : aucune
Stockholm
8
Follicum is a Swedish biotechnology company working to develop new pharmaceuticals that control hair growth
Follicum’s lead drug candidate for hair growth inhibition, FOL- 005, is based on a large human protein which has been manipulated and modified. Undesired hair growth (hirsutism, hypertrichosis) can cause major psychological distress in both women and men. Only few and often unsatisfactory therapeutic options are currently available, new treatment strategies need to be developed.
Independent in-vitro studies with FOL-005 at a leading universities in German and Israel, showed effective inhibition of hair growth on living human skin tissue.
As this peptide drug candidate is based on an endogenous protein that will be broken down by the body it is predicted that it will have no serious adverse effects on either men or women and to date no adverse reactions have been seen in the preclinical studies. Also initial short term toxicological studies have not shown any negative effects. The project has just entered the first clinical trial at Charité, Berlin, Germany.
ALENFALL Jan
www.follicum.seen
FOLLI:SS

Fiche créée le 10/04/2016 par Guillaume   vue 9 fois.